Rankings
▼
Calendar
PRME
Prime Medicine, Inc.
$771M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$205M
Net Income
-$198M
EPS (Diluted)
$-2.18
Cash Flow
Operating Cash Flow
-$165M
Free Cash Flow
-$174M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$194M
Total Liabilities
$61M
Stockholders' Equity
$133M
Cash & Equivalents
$42M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$205M
-$117M
-75.7%
Net Income
-$198M
-$122M
-62.6%
← Q4 2022
All Quarters
Q1 2023 →
PRME FY 2023 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena